Definium Therapeutics (DFTX) Study result summary
Event summary combining transcript, slides, and related documents.
Study result summary
14 Sep, 2026Unmet need and study background
Generalized anxiety disorder (GAD) prevalence has increased from 3% to 10% over 20 years, with no new drugs approved since 2007.
GAD imposes significant impairment in daily functioning, work productivity, and quality of life.
GAD remains a significant unmet need, with little innovation since 2007.
Study overview, design, and population
Panorama was a Phase 3, multicenter, randomized, double-blind, placebo-controlled study evaluating DT120 ODT 100 µg, 50 µg, and placebo in adults with GAD.
The study included a 12-week double-blind period and a 40-week open-label extension, with up to four additional doses based on symptom severity.
245 participants aged 18–74 were randomized; baseline characteristics reflected severe anxiety and high prior treatment burden.
No psychotherapeutic intervention was provided; participants were tapered off background medications before enrollment.
The primary endpoint was change from baseline in HAM-A total score at week 12, assessed by independent central raters.
Efficacy results
DT120 ODT 100 µg achieved a statistically significant placebo-adjusted reduction in HAM-A score of 5.1 points at week 12 (p<0.0001, Cohen's d=0.64); rapid efficacy was observed as early as day 2.
Key secondary endpoints were met, including significant improvements in CGI-S and early HAM-A scores.
At week 12, response and remission rates were higher for DT120 ODT 100 µg (response: 32% vs 14%; remission: 15% vs 4% vs placebo).
Efficacy was consistent across subgroups, including those with multiple prior GAD treatments.
The 50 µg dose showed less efficacy and did not meet the efficacy target; dose response was consistent with prior studies.
Latest events from Definium Therapeutics
- DT120 targets a one-to-three-dose model, with an H1 2027 NDA plan and a 2027 MDD readout.DFTX
Jefferies Global Healthcare Conference - Positive DT120 Phase 3 results support a targeted 1H 2027 NDA filing.DFTX
Corporate presentation - DT120 targets an H1 2027 NDA; early DT402 findings support continued ASD development.DFTX
Stifel 2026 Healthcare Conference 2026 - Phase 3 DT120 results support an H1 2027 NDA target, with $1.05B projected to fund operations into 2030.DFTX
Q3 2026 - DT120 demonstrated strong efficacy and safety in GAD and MDD, with durable benefits and flexible dosing.DFTX
TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit - DT120 ODT demonstrated best-in-class efficacy and safety in GAD and MDD, with NDA filing planned for 2027.DFTX
Corporate presentation - DT120 ODT delivers best-in-class efficacy and safety in GAD and MDD, supporting blockbuster potential.DFTX
Corporate presentation - DT120 ODT showed rapid, robust, and durable efficacy in GAD with strong safety and long-term benefits.DFTX
Study result - Record Phase 3 MDD efficacy, $1.1B cash, and GAD data drive continued pipeline momentum.DFTX
Q2 2026